NAS10028,945+0.02%S&P7,552−0.45%GOLD$4,296−0.86%BTC$75,632+0.03%VIX17.71+2.97%live tape · as of 23:00 UTC
The Screen · Healthcare · Medical Care Facilities
Universal Health Services
UHS · a US exchange · USD · Market cap $10.2B · 101,500 employees
Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities in the United States.
Screened 2026-09-10 · the tape above runs as of 23:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Universal Health Services holds its Accumulation at $172.72. The statistical read favours the sellers, held for 19 days.
As held on the ledger · 2026-09-10
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 19 days
Price at the screen
$172.72
Valuation
7.05 trailing · 7.19 forward price to earnings
Values screen
PASS· score 83.1
Beta
1.06
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
33.27%
Below 33%
Interest-bearing debt is just 33.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
17.65%
Below 49%
Money owed to the company is 17.6% of assets, under the 49% limit.
Pass
Revenue purity
0.01%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OPPORTUNITY: it trades at roughly a 38% discount to our $238.75 fair value, narrow competitive moat, 8.30% revenue growth.
Fair value range in USD, drawn from the 2026-09-10 screen. The gold marker is the market price at the same screen. A 38.2% margin of safety to the base estimate.
Third-party analyst targets: 17 covering, consensus Buy. The average target sits +11% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-10 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
US hospitals priced like a broken business
Walk into any busy US emergency room and the operator behind the scenes is often grinding through thin margins to keep beds full. Universal Health Services runs acute care hospitals and behavioural facilities across the country, yet the shares sit at a forward multiple of just 6 times earnings with revenue climbing 10 percent and return on equity at 21 percent.
That valuation gap to our fair value of 255 dollars looks wide for a business that passes every ethical check and carries a narrow moat. Seventeen analysts already lean buy with a median target of 204 dollars, but the market still prices in far more trouble than the cash generation suggests.
The catch is reimbursement pressure and labour costs that can swing quickly in healthcare, plus the narrow moat leaves room for local competitors to chip away. Even strong returns can fade if policy shifts hit harder than expected.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
UHS trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (17 analysts) rates it buy, with a mean price target of $194.
2026-08-15Markup · changed$169.72+16.9%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 16.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (16 analysts) rates it buy, with a mean price target of $221.
2026-07-18Distribution$145.17+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (16 analysts) rates it buy, with a mean price target of $221.
2026-07-03Distribution$145.17+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$145.17Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
